中文摘要：

本试验通过建立多杀性巴氏杆菌感染的小鼠肺炎模型,研究马波沙星在肺部感染小鼠体内的血浆、肺组织、上皮细胞衬液的药动学。小鼠肺部感染多杀性巴氏杆菌后,单剂量皮下注射10 mg/kg的马波沙星。采用高效液相色谱法测定血浆、肺组织、支气管肺泡灌洗液中的药物浓度,用WinNonLin5.2.1软件提供的非房室模型处理药物浓度—时间数据。结果显示,血浆中的主要药代动力学参数达峰时间（t_（max））为0.5 h,达峰浓度（C_（max））为3.58 g/m L,药时曲线下面积（AUC0-24h）为6.91 g/（mL·h）,消除半衰期（t1/2β）为2.87 h;肺组织中的主要药代动力学参数tmax为0.25 h,C_（max）为8.14 g/m L,AUC0-24 h为15.89 g/（m L·h）,t1/2β为3.56 h;上皮细胞衬液（ELF）中的主要药代动力学参数tmax为0.5 h,Cmax为3.89 g/m L,AUC0-24h为9.58 g/（m L·h）,t_（1/2β）为1.98 h,ELF中AUC与血浆游离药物AUC的比值为1.98。结果表明,马波沙星在肺部渗透能力较强,这为马波沙星治疗呼吸道感染提供了实验依据。

英文摘要：

This study was conducted to evaluate the pharmacokinetic characteristics of marbofloxacin in plasma, lung tissue and epithelial lining fluid（ELF）in a murine lung infection model.Marbofloxacin was administrated to the mice infected with Pasteurella multocida subcutaneously at a single dosage of 10 mg/kg body weight. Marbofloxacin concentration in the plasma, lung tissue and bronchoalveolar lavage fluid（BLAF） was measured by high performance liquid chromatography, and drug concentration-time data were analyzed by using the non-compartment model in Win Non Lin5.2.1 software. The main plasma pharmacokinetic parameters were as follows： the tmax was 0.5 h; the maximum concentration（C_（max）） was 3.58 g/m L; the area under the plasma drug concentration-time curve（AUC0-24h） was 6.91 g/（m L·h）and the elimination half-life（t_（1/2β）） was 2.87 h. The main pharmacokinetic parameters in lung tissue were as follows： the t_（max） was 0.25 h; Cmaxwas 8.14 g/m L; AUC0-24 hwas 15.89 g/（m L·h） and t_（1/2β） was 3.56 h.The main pharmacokinetic parameters in ELF were as follows： tmaxwas 0.5 h; Cmaxwas 3.89 g/ m L; AUC0-24 hwas 9.58g/（mL ·h）; t_（1/ 2β） was 1.98 h and the value of AUCELF/ fA UCplasmawas 1.98. The result showed that the penetration of marbofloxacin in ELF was relatively high and the ratio ELF-free plasma AUC0-24 was about 2, providing experimental data when marbofloxacin is used in the treatment of respiratory disease.